Provided by Tiger Trade Technology Pte. Ltd.

Tempest Therapeutics Inc.

1.10
+0.06005.77%
Post-market: 1.07-0.0254-2.31%16:58 EDT
Volume:198.80K
Turnover:217.43K
Market Cap:17.58M
PE:-0.24
High:1.14
Open:1.05
Low:1.01
Close:1.04
52wk High:12.23
52wk Low:0.8401
Shares:15.98M
Float Shares:9.04M
Volume Ratio:0.65
T/O Rate:2.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.5617
EPS(LYR):-19.4955
ROE:-931.14%
ROA:-79.37%
PB:-16.13
PE(LYR):-0.06

Loading ...

Tempest Therapeutics CEO Matthew Angel reports indirect purchase of 231,482 shares for $499,999.12

Reuters
·
Jun 24

Tempest Therapeutics shareholders approved Nasdaq Rule 5635 share issuances at special meeting

Reuters
·
Jun 23

Tempest Therapeutics director John D. Yee files initial beneficial ownership statement

Reuters
·
Jun 18

Tempest Therapeutics director William Drake Richey files initial beneficial ownership statement

Reuters
·
Jun 09

Tempest Therapeutics - Nicholas Maestas Resigns as CFO Effective June 5, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 05

Tempest Therapeutics adds Drake Richey, John Yee to board

Reuters
·
Jun 05

Tempest Therapeutics Appoints Drake Richey and John Yee, Md, Mph to Board of Directors

THOMSON REUTERS
·
Jun 05

Tempest Therapeutics issues unregistered warrant for up to 2,344,828 shares in inducement deal

Reuters
·
Jun 02

Tempest Therapeutics director Simantov resigns from board

Reuters
·
May 30

Tempest Therapeutics announces exercise of 1,172,414 warrants at reduced $1.73 per share price

Reuters
·
May 29

Tempest Therapeutics gets Nasdaq notice for failing $2.5 million equity rule

Reuters
·
May 23

Tempest Therapeutics directors Brady, Raab, Pellizzari resign from board

Reuters
·
May 23

Tempest Risk Solutions Appoints David Näslund As CEO

Reuters
·
May 20

Tempest net loss widens 155% to $27.7 million in Q1 2026

Reuters
·
May 15

Tempest Therapeutics Q1 net loss widens on asset acquisition costs

Reuters
·
May 15

Tempest Therapeutics Q1 Operating Income USD -27.719 Million

THOMSON REUTERS
·
May 15

Press Release: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 15

Tempest Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
May 08

Tempest says TPST-2003 dual-target CAR-T hits 100% complete response in Phase 1 trials

Reuters
·
May 06

Jakarta, Danantara Sign Rp17.4 Trillion Waste-to-Energy Deal

Tempo
·
May 05